GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Myriad Genetics Inc (FRA:MYD) » Definitions » Sale Of Property, Plant, Equipment

Myriad Genetics (FRA:MYD) Sale Of Property, Plant, Equipment : €0.0 Mil (TTM As of Mar. 2024)


View and export this data going back to 1995. Start your Free Trial

What is Myriad Genetics Sale Of Property, Plant, Equipment?

Myriad Genetics's sale of property, plant, equipment for the three months ended in Mar. 2024 was €0.0 Mil. It means Myriad Genetics gained €0.0 Mil from selling property, plant, and equipment. Myriad Genetics's sale of property, plant, equipment for the trailing twelve months (TTM) ended in Mar. 2024 was €0.0 Mil.

Compared with last quarter (€0.0 Mil in Dec. 2023 ), Myriad Genetics gained the same money from selling property, plant, and equipment in Mar. 2024 (€0.0 Mil).

Myriad Genetics Sale Of Property, Plant, Equipment Historical Data

The historical data trend for Myriad Genetics's Sale Of Property, Plant, Equipment can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Myriad Genetics Sale Of Property, Plant, Equipment Chart

Myriad Genetics Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Dec21 Dec22 Dec23
Sale Of Property, Plant, Equipment
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Myriad Genetics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Sale Of Property, Plant, Equipment Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Myriad Genetics Sale Of Property, Plant, Equipment Calculation

The amount earned to sell PPE.

Sale Of Property, Plant, Equipment for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Myriad Genetics Sale Of Property, Plant, Equipment Related Terms

Thank you for viewing the detailed overview of Myriad Genetics's Sale Of Property, Plant, Equipment provided by GuruFocus.com. Please click on the following links to see related term pages.

Myriad Genetics (FRA:MYD) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Myriad Genetics Inc (FRA:MYD) » Definitions » Sale Of Property, Plant, Equipment
Comparable Companies
NEO VCYT TWST GH LAB OPK NEOG FLGT CSTL CDNA TMO DHR IQV XSWX:LONN IDXX A MTD ICLR ILMN WAT
Traded in Other Exchanges
MYGN:USA
Address
320 Wakara Way, Salt Lake City, UT, USA, 84108
Website
https://www.myriad.com
Myriad Genetics is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel with the capability to identify the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm offers biomarker discovery and companion diagnostic services to pharma and biotech companies.